
PTGX
Healthcare · Biotechnology · $8.55B market cap
$130.95-3.43 (-2.6%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +44.9% over 90 days · 30-day revisions 0 up, 3 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 5, 2026 | After the close | 2.58 | 3.07 | +19.0% |
| Aug 5, 2026 | After the close | 2.11 | 2.29 | +8.5% |
| May 5, 2026 | After the close | -0.65 | 0.05 | +107.7% |
| Mar 18, 2026 | Time not confirmed | -0.34 | -0.69 | -102.8% |
| Nov 6, 2025 | After the close | -0.64 | -0.62 | +3.1% |
| Aug 6, 2025 | After the close | -0.52 | -0.55 | -5.8% |
| May 6, 2025 | After the close | 0.11 | -0.19 | -272.7% |
| Feb 25, 2025 | After the close | 0.25 | 1.98 | +692.0% |
| Nov 7, 2024 | After the close | -0.53 | -0.54 | -1.9% |
| Aug 6, 2024 | Before the open | -0.41 | -0.50 | -22.0% |
| May 7, 2024 | After the close | 1.60 | 3.26 | +103.8% |
| Feb 27, 2024 | After the close | -0.03 | 0.44 | +1566.7% |
| Nov 2, 2023 | After the close | -0.70 | -0.58 |
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development…
| +17.1% |
| Aug 3, 2023 | After the close | -0.66 | -0.68 | -3.0% |
| May 4, 2023 | After the close | -0.70 | -0.67 | +4.3% |
| Mar 15, 2023 | After the close | -0.64 | -0.69 | -7.8% |
| Nov 8, 2022 | After the close | -0.85 | -0.64 | +24.7% |
| Aug 4, 2022 | After the close | -0.98 | -0.84 | +14.3% |
| May 4, 2022 | After the close | -0.60 | -0.43 | +28.3% |
| Feb 28, 2022 | After the close | -0.78 | -0.77 | +1.3% |
| Nov 3, 2021 | After the close | -0.66 | -0.70 | -6.1% |
| Aug 4, 2021 | After the close | -0.53 | -0.69 | -30.2% |
| May 4, 2021 | After the close | -0.56 | -0.54 | +3.6% |
| Mar 10, 2021 | After the close | -0.48 | -0.48 | 0.0% |
| Nov 4, 2020 | After the close | -0.56 | -0.21 | +62.5% |
| Aug 6, 2020 | After the close | -0.58 | -0.57 | +1.7% |
| May 7, 2020 | After the close | -0.69 | -0.72 | -4.3% |
| Mar 10, 2020 | After the close | -0.70 | -0.63 | +10.0% |
| Nov 6, 2019 | After the close | -0.73 | -0.61 | +16.4% |
| Aug 7, 2019 | Before the open | -0.27 | -1.18 | -337.0% |
| May 8, 2019 | Before the open | -0.59 | -0.58 | +1.7% |
| Mar 12, 2019 | After the close | -0.47 | -0.57 | -21.3% |
| Nov 6, 2018 | After the close | -0.33 | -0.38 | -15.2% |
| Aug 7, 2018 | After the close | -0.29 | -0.41 | -41.4% |
| May 9, 2018 | After the close | -0.24 | -0.36 | -50.0% |
| Mar 7, 2018 | After the close | -0.35 | -0.15 | +57.1% |